Elsevier’s ClinicalPath is now a Recognized Quality Solution for the ASCO Certified Program

Elsevier today announced that ClinicalPath, its oncology decision support solution, has been designated a Recognized Quality Solution (RQS) by the Association for Clinical Oncology for the ASCO Certified program, reinforcing its role in advancing high-quality, patient-centered cancer care.

Omry Bigger, President, Clinical Solutions, Elsevier said “Cancer practices want to deliver the best care possible, and this recognition means they can be even more confident in the value ClinicalPath provides. Being able to support cancer practices with their reporting requirements is a crucial element of the RQS designation, and we look forward to taking this step forward with our customers.”

Clifford A. Hudis, MD, FACP, FASCO, CEO of ASCO said, "We are pleased to designate Elsevier's ClinicalPath as a Recognized Quality Solution. ClinicalPath underwent a rigorous validation process that reviewed the necessary data elements for clinical quality measurement and pathway utilization. This recognition demonstrates Elsevier's commitment to assisting practices with meeting certification requirements."

With ClinicalPath, cancer centers can:

• Deliver consistent high-quality, patient-centered care aligned with ASCO Certified standards

• Leverage evidence-based pathways driven by the latest research, updated content, and integrated clinical trials

• Streamline quality reporting and compliance with automated capture of pathway utilization and on/off pathway data

• Enhance credibility and align with payers through support for value-based care models

You can find out more about ClinicalPath here.

About ASCO Certified

ASCO Certified is a practice certification demonstrating oncology patient-centered care based on the Oncology Medical Home (OMH) Standards from the American Society of Clinical Oncology and the Community Oncology Alliance (COA). These standards aim to establish core elements needed to deliver high-quality cancer care and achieve broad consensus among all stakeholders on what patients with cancer should expect and receive from their cancer care teams.

エルゼビアについて

エルゼビアは、先端情報と意思決定を支援しています。1世紀以上にわたり、人類の進歩のため先端科学とヘルスケアの進歩に貢献してきました。私たちは、170か国にわたるアカデミアや企業の研究コミュニティ、医師、看護師、未来の医療従事者、教育者の皆さまの重要な活動をサポートしています。これは、信頼できるエビデンスに基づく科学・医療コンテンツと高度なAI技術を組み合わせた革新的なソリューションにより知見の集積や重要な意思決定を支援することで実現しています。また、私たちは、これらの価値を製品や企業文化に組み込み、コミュニティとの協働を通じて、インクルージョンと持続可能性を推進しています。エルゼビア財団は、世界中の研究と医療のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Groupの一事業を担っています。詳細につきましては、www.elsevier.comまたはソーシャルメディア@Elsevier Connectをご覧ください。